How AI can improve care, limit unnecessary surgeries for patients with kidney tumors

Machine learning-based CT texture analysis can help with the evaluation of solid renal masses, according to new findings published in Academic Radiology. Could this help reduce the number of patients undergoing unnecessary surgeries?

Specialists typically assume solid renal masses are malignant, ordering that they be surgically removed to save the patient any further harm. But as many as 16% of those masses end up being benign, leading researchers to seek more precise noninvasive ways to differentiate between malignant and benign findings.   

“Texture analysis, or the pixel-scale quantitative evaluation of repetitive morphological patterns that cannot be assessed by humans, may provide an answer to the problems caused by the current inability to distinguish benign and malignant solid renal masses,” wrote lead author Cagri Erdim, MD, Sultangazi Haseki Training and Research Hospital in Turkey, and colleagues. “A growing body of evidence in recent studies has shown that the textural characteristics obtained from the computerized analysis of images may be associated with the histopathological characteristics of the disease. In this context, combining the texture analysis with AI or machine learning algorithms might be an exciting venture that may yield promising benefits for renal mass characterization.”

The team analyzed data from 79 patients with a total of 84 solid renal masses. All patients were treated at the same facility from January 2013 to May 2018. The analysis of unenhanced and contrast-enhanced CT images led to the extraction of 271 texture features. Eight machine learning algorithms—decision tree, locally weighted learning, k-nearest neighbors, naive Bayes, logistic regression, support vector machine, neural network, and random forest—were then used for classification purposes.

Overall, 198 features with good reproducibility came from the unenhanced CT images, and 244 came from the contrast-enhanced CT images. Also, the team found that the algorithm with the best performance, random forest, achieved an accuracy of 90.5% and an area under the ROC curve of 0.915.

“Our findings indicate that quantitative CT texture analysis with machine learning-based classification algorithms can be useful for the noninvasive discrimination of benign and malignant solid renal masses,” the authors wrote. “Using the random forest method on corticomedullary phase contrast-enhanced CT images, we were able to correctly identify benign and malignant cases in about nine-tenths of the patients.”

There were certain limitations to the team’s research. It was a retrospective study, for instance, and the sample size was “relatively small.” Also, two different scanners were used to image patients, though the same imaging protocols were followed at all times.

“Lastly, we used an internal dataset for both training and testing,” the authors added. “To overcome potential bias, we performed a nested cross-validation procedure. However, the adoption of independent external datasets or the use of two sets of patients (one for training, one for testing) would provide further validation of the classifiers used in the study.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.